
NeoGenomics, Inc.
NEO
Updated: 04/11/2026, 20:06:22
No historical data available
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
No summaries found.
- Share price
- $17.10
- Market cap
- $2.23B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Anthony Zook
- Employees
- 2,500
- IPO date
- 16/03/2004
- Beta
- 1.834
- Last dividend
- $0.00
- Day range
- $16.60 – $17.39
- 52-week range
- $7.07 – $20.15
- 1-day performance
- 1.60%
- 1-year performance
- 141.87%
- Current drawdown (1Y)
- -15.14%
- CIK
- 0001077183
- CUSIP
- 64049M209
- ISIN
- US64049M2098
- Created
- 07/12/2025, 05:25:20
- Last update
- 04/11/2026, 20:06:22
Track NeoGenomics, Inc. with an AI analyst
See which prediction-market events move NEO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
NeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100
GuruFocus • STOCK • 28/05/2026, 22:54:00
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
GlobeNewsWire • STOCK • 20/05/2026, 18:20:00
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 29/04/2026, 05:51:32
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
Business Wire • STOCK • 23/04/2026, 09:05:00
Neo Energy Metals shares surge 33% as ex-Sibanye chief Froneman joins as chairman
Proactive Investors • STOCK • 22/04/2026, 06:45:59
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
Business Wire • STOCK • 13/04/2026, 09:05:00
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
Business Wire • STOCK • 07/04/2026, 09:05:00
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
Business Wire • STOCK • 25/02/2026, 08:05:00
Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
Business Wire • STOCK • 23/02/2026, 07:00:00
NeoGenomics to Participate in Upcoming Investor Conferences
Business Wire • STOCK • 18/02/2026, 08:05:00
NeoGenomics, Inc. (NASDAQ:NEO) Financial Performance Analysis
Market Data • Market Data • 17/02/2026, 18:00:05
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research • STOCK • 17/02/2026, 10:16:08